Navigation Links
OHSU Knight Cancer Institute to study new radiation technology for head, neck cancer
Date:4/28/2009

PORTLAND, Ore. The Oregon Health & Science University Knight Cancer Institute will evaluate whether the state-of-the-art image-guidance system called Calypso (Calypso Medical, Seattle, Wash.) is as effective in delivering highly precise radiation therapy to head and neck cancer patients as it has been in those with prostate cancer.

"We have been extremely happy with the system's performance for prostate cancer, and it is our hope to apply this system to multiple new body sites in the future. This study represents a real first step in that direction," said Patrick Gagnon, M.D., principal investigator and co-chief resident in the Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine.

The Calypso system relies on three electromagnetic transponders, or beacons, about the size of a grain of rice that are implanted in the prostate prior to beginning treatments. These transponders utilize electromagnetic fields that can be detected with sub-millimeter precision for accurate daily targeting of the prostate gland. Continuous monitoring of the patient and prostate motion is also possible, which allows for greater accuracy in delivering radiation therapy and limits exposure to surrounding healthy tissue.

In this new Phase II clinical trial, the beacons will be implanted into a customized mouth guard fitted to the participant's upper teeth/jaw. With the mouth guard in place, the research team will test whether daily patient positioning can be improved using this system. They will be able to monitor the participant's movement in real time throughout the seven-week course of treatment. This has proved difficult in the past without exposing the patient to additional radiation.

"The Calypso system is unique in allowing the treatment team to continuously monitor the patient's position as the procedure is under way. Unlike other technologies, it doesn't require additional radiation exposure to provide the movement and localization feedback we need," explained Gagnon.

This new research is funded in part through a grant from The American Society of Clinical Oncology (ASCO) Cancer Foundation, which recently awarded Gagnon its highly coveted 2009 Young Investigator Award for his groundbreaking work in this area.

"Only about 30 of these awards are given nationally each year, and only two to four go to radiation oncology junior faculty/trainees. We are proud of Dr. Gagnon's achievement and are excited to be able to offer this leading-edge technology to another group of cancer patients," said Charles Thomas, M.D., chairman of the Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine.

Gagnon will partner with Thomas and John Holland, M.D., associate professor, Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine, in conducting this research.

This work is supported by The ASCO Cancer Foundation Award. Any opinions, findings, conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology or The ASCO Cancer Foundation.


'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Intrepid USA Healthcare Services Appoints Kathy McKnight as Chief Operations Officer
2. Knights of Columbus to Distribute Wheelchairs to Veterans in Need
3. Knights to Distribute $1 Million Worth of Wheelchairs for Veterans
4. Knights Distribute $1 Million Worth of Wheelchairs to Veterans
5. Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
6. Jane M. Knight Recognized By Strathmores Whos Who Worldwide Publication
7. Perr&Knight Announces Discounted Fee Schedule for Access to Its Online Database of Commercial Lines Competitor Filings
8. UF McKnight Brain Institute director honored by Italian scientists
9. Holland & Knight Welcomes MARC Associates - Experts in Health Care and Intergovernmental Policy - to the Firms Public Policy & Regulation Practice
10. Knights of Columbus Ultrasound Program Assists Pregnant Women
11. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: